Data Foundry

Drug recalls 2022

Amlodipine and Olmesartan Medoxomil Tablets — Class II drug recall D-0632-2022

Terminated recall by Macleods Pharma Usa Inc, reported 2022-03-09, distributed nationwide. cGMP deviations

Recall numberD-0632-2022
Product typeDrug
ClassificationClass II
StatusTerminated
Voluntary or mandatedVoluntary
Recalling firmMacleods Pharma Usa Inc, Plainsboro, NJ, United States
Recall initiated2022-02-15
Classified2022-02-25
Reported by FDA2022-03-09
Terminated2023-02-17
DistributedNationwide (US)
Quantity3,672 bottles
Reason classescgmp
NDC33342-0190, 33342-0190-07, 33342-0190-10, 33342-0190-12, 33342-0190-44, 33342-0191, 33342-0191-07, 33342-0191-10, 33342-0191-12, 33342-0191-44, 33342-0192, 33342-0192-07, 33342-0192-10, 33342-0192-12, 33342-0192-44, 33342-0193, 33342-0193-07, 33342-0193-10, 33342-0193-12, 33342-0193-44
Lot numbersBAD62101A
Expiration dates2024-02

Product

Amlodipine and Olmesartan Medoxomil Tablets, 10 mg /20 mg, 30-count bottles, Rx only, Manufactured for: Macleods Pharma USA, Inc., Plainsboro, NJ 08536, Manufactured by: Macleods Pharmaceuticals, Ltd, Baddi, Himachal Pradesh, INDIA, NDC 33342-192-07.

Reason for recall

cGMP deviations

Machine access

This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0632-2022. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.

Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.